CN114867846A - 多靶向效应细胞和其用途 - Google Patents

多靶向效应细胞和其用途 Download PDF

Info

Publication number
CN114867846A
CN114867846A CN202080080349.4A CN202080080349A CN114867846A CN 114867846 A CN114867846 A CN 114867846A CN 202080080349 A CN202080080349 A CN 202080080349A CN 114867846 A CN114867846 A CN 114867846A
Authority
CN
China
Prior art keywords
cells
cell
derived
car
bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080349.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·瓦拉梅尔
R·比乔戴尔
J·古德里奇
T·T·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of CN114867846A publication Critical patent/CN114867846A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080080349.4A 2019-09-25 2020-09-25 多靶向效应细胞和其用途 Pending CN114867846A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906046P 2019-09-25 2019-09-25
US62/906,046 2019-09-25
US201962944187P 2019-12-05 2019-12-05
US62/944,187 2019-12-05
PCT/US2020/052890 WO2021062281A2 (en) 2019-09-25 2020-09-25 Multi-targeting effector cells and use thereof

Publications (1)

Publication Number Publication Date
CN114867846A true CN114867846A (zh) 2022-08-05

Family

ID=75166460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080349.4A Pending CN114867846A (zh) 2019-09-25 2020-09-25 多靶向效应细胞和其用途

Country Status (11)

Country Link
US (1) US20220378831A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034638A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022548943A (cg-RX-API-DMAC7.html)
KR (1) KR20220085779A (cg-RX-API-DMAC7.html)
CN (1) CN114867846A (cg-RX-API-DMAC7.html)
AU (1) AU2020353166A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005602A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149585A1 (cg-RX-API-DMAC7.html)
IL (1) IL291484A (cg-RX-API-DMAC7.html)
MX (1) MX2022003414A (cg-RX-API-DMAC7.html)
WO (1) WO2021062281A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368520A (zh) * 2015-11-04 2018-08-03 菲特治疗公司 多能细胞的基因组工程改造
WO2024099265A1 (zh) * 2022-11-07 2024-05-16 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
WO2025021201A1 (en) * 2023-07-26 2025-01-30 BRL Medicine Inc. Method and composition for treating diseases

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP4097220A4 (en) * 2020-01-30 2024-03-20 ImmunityBio, Inc. ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
JP2024522756A (ja) * 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
GB202110363D0 (en) * 2021-07-19 2021-09-01 Celyad S A NKG2D CAR cells expressing IL-18 for adoptive cell therapy
CA3228865A1 (en) * 2021-08-18 2023-02-23 Bahram Valamehr Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody
JP2024539013A (ja) * 2021-10-20 2024-10-28 フェイト セラピューティクス,インコーポレイティド 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
US20250018034A1 (en) * 2021-11-08 2025-01-16 Fate Therapeutics, Inc. Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
WO2024004814A1 (en) * 2022-06-27 2024-01-04 Kyoto University A METHOD FOR PRODUCING iPS CELL -DERIVED NATURAL KILLER CELLS
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
EP4593868A1 (en) * 2022-09-26 2025-08-06 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2025109493A1 (en) * 2023-11-21 2025-05-30 National University Of Singapore Chimeric Receptors with Binding Capacity for Antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130156770A1 (en) * 2011-11-15 2013-06-20 Boehringer Ingelheim International Gmbh Binding molecules for bcma and cd3
CN106661109A (zh) * 2014-04-30 2017-05-10 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 抗cd269(bcma)人源化抗体
CN109641012A (zh) * 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
WO2019126748A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130156770A1 (en) * 2011-11-15 2013-06-20 Boehringer Ingelheim International Gmbh Binding molecules for bcma and cd3
CN106661109A (zh) * 2014-04-30 2017-05-10 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 抗cd269(bcma)人源化抗体
US20170166649A1 (en) * 2014-04-30 2017-06-15 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Humanized antibodies against cd269 (bcma
CN109641012A (zh) * 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
WO2019126748A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368520A (zh) * 2015-11-04 2018-08-03 菲特治疗公司 多能细胞的基因组工程改造
CN108368520B (zh) * 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
WO2024099265A1 (zh) * 2022-11-07 2024-05-16 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
WO2025021201A1 (en) * 2023-07-26 2025-01-30 BRL Medicine Inc. Method and composition for treating diseases

Also Published As

Publication number Publication date
US20220378831A1 (en) 2022-12-01
CA3149585A1 (en) 2021-04-01
EP4034638A4 (en) 2024-07-17
IL291484A (en) 2022-05-01
WO2021062281A2 (en) 2021-04-01
EP4034638A2 (en) 2022-08-03
KR20220085779A (ko) 2022-06-22
MX2022003414A (es) 2022-04-18
JP2022548943A (ja) 2022-11-22
BR112022005602A2 (pt) 2022-07-19
AU2020353166A1 (en) 2022-03-24
JP2026041849A (ja) 2026-03-10
WO2021062281A3 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
KR102817092B1 (ko) 조작된 면역 효과기 세포 및 이의 용도
US20250145966A1 (en) Enhanced immune effector cells and use thereof
US20220378831A1 (en) Multi-targeting effector cells and use thereof
CN114258429A (zh) 免疫效应细胞工程化和其用途
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
CN114901693A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
CN113166232A (zh) 使用增强的iPSC衍生效应细胞的免疫疗法
AU2021372975A9 (en) Engineered ipsc and persistent immune effector cells
HK40071271A (en) Multi-targeting effector cells and use thereof
HK40063194A (en) Immune effector cell engineering and use thereof
HK40033113A (en) Engineered immune effector cells and use thereof
HK40051439A (en) Immunotherapies using enhanced ipsc derived effector cells
HK40025663A (en) Enhanced immune effector cells and use thereof
HK40039347A (en) Enhanced immune effector cells and use thereof
HK40039347B (en) Enhanced immune effector cells and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40071271

Country of ref document: HK